Clearside Biomedical Publishes Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS) Injection

Clearside Biomedical announced that new guidelines that represent best practices for injection into the suprachoroidal space have been published in "RETINA, The Journal of Retinal and Vitreous Diseases." The publication, entitled, “Suprachoroidal Space Injection Technique: Expert Panel Guidance,” was co-authored by 16 practicing retinal physicians led by Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, Houston, Texas.

The guidance was developed based on current published evidence and clinical experience. The panel established consensus on the rationale for SCS injection, including potential benefits relative to other intraocular delivery methods, and current best practices in patient preparation, pre- and peri-injection management, SCS specific injection techniques, and post-injection management and follow-up.

“As the pioneers of suprachoroidal delivery, we are thrilled to have this established set of jointly developed guidelines featured in the prominent journal, RETINA, which we believe supports the use of our proven delivery platform,” George Lasezkay, PharmD, JD, President and CEO of Clearside, said in a company news release. “On behalf of the entire Clearside team, we would like to thank this esteemed group of physicians whose time and effort generated such a thorough and well-supported SCS injection guidance publication.”

In addition to Dr. Wykoff, the leading global key opinion leaders in ophthalmology who contributed to the publication were: Robert L. Avery, MD; Mark R. Barakat, MD; David S. Boyer, MD; David M. Brown, MD; Alexander J. Brucker, MD; Emmett T. Cunningham, MD, PhD, MPH; Jeffrey S. Heier, MD; Nancy M. Holekamp, MD; Peter K. Kaiser, MD; Arshad M. Khanani, MD, MA; Judy E. Kim, MD; Hakan Demirci, MD; Carl D. Regillo, MD; Glenn C. Yiu, MD, PhD; and Thomas A. Ciulla, MD, MBA.

The full publication can be accessed here.